2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH DENA BATTLE
Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial

VIEW ALL ASCO GU 2019 VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH OLIVER SARTOR
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer

VIEW ALL PCF VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL ASCO GU 2019 VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

VIEW ALL ASCO GU 2019 VIDEOS

Featured Videos

#WCE2014 - Robotic assisted laparoscopic partial nephrectomy (RPN) for clinical T1b renal masses: A retrospective cohort review - Interview

TAIPEI, TAIWAN (UroToday.com) - Introduction and Objectives: Robotic assisted laparoscopic partial nephrectomy (RPN) is becoming the standard of care in the management of small renal masses. We aimed to evaluate the safety, efficacy, and oncologic outcome of RALPN for clinical T1b renal masses.

wceMethods: 119 patients who underwent robotic partial nephrectomy by a single surgeon at our institution from 2011 to 2014 were retrospectively reviewed Perioperative parameters and demographic data for clinical T1a and T1b (21 patients) masses were obtained from chart review and compared using Student’s t-test and Fisher’s exact test.

Results: For clinical T1b patients tumor size (5.3 cm vs. 2.3 cm, p < 0.0001) R.E.N.A.L nephrometry score (6.8 vs. 5.4, p = 0.009), and previous abdominal surgery (29 % vs. 86 % p < 0.0001) were all significantly different. Perioperative parameters that were statistically significant were operative time (242 min vs. 203 min, p = 0.010) and length of hospital stay (4.1 vs. 3.5 d, p = 0.002). There was one positive margin in T1b group compared to none T1a group. Inability to complete robotic partial in the T1b cohort was 25% vs. 7% in the T1a cohort (p = 0.030) including difference in conversion to open partial 19% vs. 6.1% (p = 0.050). There was greater percentage of Clavien I-III complications in the T1b cohort (24% vs. 9% p = 0.055).

Conclusions: RPN for patients with cT1b renal masses is safe and efficacious. Operative time and hospital stay were longer for patients with cT1b masses as well as need to convert to open partial nephrectomy. When counseling patients with cT1b renal masses, RPN should be considered a feasible option.

Source of Funding: None

 
View an interview with Timothy Tran, one of the authors of this study.

 

Presented by Andrew Leone, Timothy Tran, George Turini, Joseph Renzulli, Gyan Pareek, and Dragan Golijanin at the 32nd World Congress of Endourology & SWL - September 3 - 7, 2014 - Taipei, Taiwan

Alpert Medical School at Brown University, Division of Minimally Invasive Urology, Providence, RI USA 

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe